© ACCESS Newswire
12.12.2025
VSEE
LISTED
NASDAQ
VSee Health, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement
News Preview
SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE, VSEEW), a leading provider of telehealth and digital health solutions, today announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Minimum Equity Rule").As previously disclosed, on September 2, 2025, the Company recei...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
GMAB
LISTED
NASDAQ
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
News Preview
Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2025
PPGN
LISTED
SIX
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
News Preview
PolyPeptide Group
/ Key word(s): Alliance
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
12.12.2025 / 07:00 CET/CEST
Media release
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Pept......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
12.12.2025
EL
LISTED
EURONEXT
EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint
News Preview
EssilorLuxottica to acquire Signifeye,further growing its ophthalmology clinics footprint...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
12.12.2025
GMAB
LISTED
CPH
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Announces Pricing of Public Offering
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,00...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
CTNM
LISTED
NASDAQ
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
News Preview
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A commo...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.12.2025
ATPC
LISTED
OTC
Agape ATP Corporation Issues Statement on Recent Market Activity and Reaffirms Strategic Outlook
News Preview
KUALA LUMPUR, MY / ACCESS Newswire / December 12, 2025 / Agape ATP Corporation (NASDAQ:ATPC) ("ATPC" or "the Company") a provider of health and wellness products and sustainable energy solutions, today issued a statement addressing recent volatility in the trading price of its common stock.The Company confirms that its business...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
9926
LISTED
HKSE
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
News Preview
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against che...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
RZLT
LISTED
NASDAQ
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
News Preview
On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”).
The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (“HI”).
The n...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ITGR
LISTED
NYSE
Investor Notice: Robbins LLP Informs Investors of the Integer Holdings Corporation Securities Class Action
News Preview
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Integer Holdings Corporation (NYSE: ITGR) securities between July 25, 2024 and October 22, 2025. Integer is a leading global medical device contract manufacturer specializing in cardiac rhythm management and cardiovascular...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
1801
LISTED
HKSE
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
News Preview
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI reduction: 1.73%; weight reduction: 1.42 kg; with nominal...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.12.2025
ITGR
LISTED
NYSE
Integer Holdings Corporation Securities Fraud Class Action Result of Undisclosed Financial Problems and 32% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR), if th...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
INVA
LISTED
NASDAQ
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
News Preview
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational single-dose, oral antibiotic zoliflodacin for the treatment of uncomplicated urogenital gonorrhea in The Lancet. The trial was sponsored and led by the...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
AMGN
LISTED
NASDAQ
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
News Preview
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMGTHOUSAND OAKS, Calif., Dec. 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdo...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
News Preview
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated DoseResults Support Advancement of the Program into Phase 2 DevelopmentCombination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patientsSA...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ITGR
LISTED
NYSE
Rosen Law Firm Urges Integer Holdings Corporation (NYSE: ITGR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”). Integer is a medical device contract manufacturer.
For more information, submit a form, email a...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SIA
LISTED
TSX
Sienna Announces Offering of $250 Million of 3.524% Series F Senior Unsecured Debentures and Redemption of C$175 Million of Series B Senior Unsecured Debentures
News Preview
NOT FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
EXAS
LISTED
NASDAQ
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG)...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SGRY
LISTED
NASDAQ
Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering
News Preview
BRENTWOOD, Tenn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”) in a previously...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
VEXT
LISTED
CSE
Vext Announces Voting Results of Annual General Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("VEXT" or the "Company"), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today announced final voting results from its annual general meeting of shareholders held on December 11, 2025 in Vancouve...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
VNDA
LISTED
NASDAQ
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
News Preview
WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026. A corporate presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time)....
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 20,300 shares of its common stock. These inducement RSUs are subject to...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
APLT
LISTED
NASDAQ
Cycle Pharmaceuticals to Acquire Applied Therapeutics
News Preview
Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ELVN
LISTED
NASDAQ
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's commo...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ZTS
LISTED
NYSE
Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
EVMN
LISTED
NYSE
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
“The recent completion of our IPO puts us in a strong positi...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
CTNM
LISTED
NASDAQ
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
News Preview
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A c...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
NUZ
LISTED
ASX
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
News Preview
Highlights:FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and clinical start-up activities ahead of commencement of patient enroll...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
JYNT
LISTED
NASDAQ
The Joint Corp. Signs Asset Purchase Agreement to Sell 22 Corporate Clinics in the Southeast and Delivers Notice to Terminate APA for 45 Clinics in California
News Preview
Southeast Buyers are Existing Members of the Franchise Community, Further Increasing their Ownership Southeast Buyers are Existing Members of the Franchise Community, Further Increasing their Ownership...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
NUZ
LISTED
ASX
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
News Preview
Highlights:FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and clinical start-up activities ahead of commencement of patient enroll...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
NHPAP
LISTED
NASDAQ
National Healthcare Properties Announces Closing of New $550 Million Senior Unsecured Credit Facility
News Preview
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (the “Company” or “NHP”) announced that it has closed a $550 million senior unsecured credit facility (“Credit Facility”), comprised of a $400 million revolving credit facility and a $150 million term loan, maturing in December 2028....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
AGE
LISTED
XASE
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
News Preview
HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today ann...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CRNX
LISTED
NASDAQ
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
News Preview
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
News Preview
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its co...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BBOT
LISTED
NASDAQ
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 Inducement Plan as a material inducement to the employme...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
TERN
LISTED
NASDAQ
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
News Preview
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Announces Proposed Public Offering
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of co...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
RFL
LISTED
NYSE
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
News Preview
NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
CNC
LISTED
NYSE
Health Net Providing Special Assistance to Members and Providers Affected by The Pack Fire in California
News Preview
SACRAMENTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Following Gov. Newsom's declaration of a State of Emergency in Mono County, Health Net, one of California's most experienced Medi-Cal managed care health plans and company of Centene Corporation (NYSE: CNC), is taking immediate action to support those affected by the Pack Fire. The company's priori...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
RZLT
LISTED
NASDAQ
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Rezolute, Inc. (“Rezolute” or “the Company”) (NASDAQ: RZLT) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors....
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
RZLT
LISTED
NASDAQ
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211275328/en/
Faruqi & Faruqi is a leading national securities l...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
TVGN
LISTED
NASDAQ
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
News Preview
WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235....
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate o...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ITGR
LISTED
NYSE
ITGR BREAKING NEWS: Integer Holdings Corporation Lowered Sales Outlook Triggers Securities Fraud Class Action after Stock Drops Over 32% -- Investors are Urged to Contact BFA Law
News Preview
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.
If you invested...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CELC
LISTED
NASDAQ
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
News Preview
MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ITGR
LISTED
NYSE
Securities Fraud Investigation Into Integer Holdings Corporation (ITGR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
PCRX
LISTED
TSX
PharmaCorp Enters Letter of Intent for the Acquisition of Pharmacy Files in Western Canada
News Preview
SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Phar...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.12.2025
SKNY
LISTED
CSE
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
News Preview
VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[1]-based therapies used in obesity and metabolic disease. LIR fi...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
MAIA
LISTED
XASE
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
News Preview
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
CVS
LISTED
NYSE
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak
News Preview
Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the stateWOONSOCKET, R.I., Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health officials work to stop the spread of measles following the current outbreak in the state, CVS Health® (NYSE:CVS) is offering the measles-mumps-rubella...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
AB
LISTED
EURONEXT
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
News Preview
PRESS RELEASE...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.12.2025
XBIO
LISTED
NASDAQ
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
News Preview
Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficu...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
1952
LISTED
HKSE
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
News Preview
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BIOPOR
LISTED
CPH
Changes to the Executive Management
News Preview
December 11, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ERAS
LISTED
NASDAQ
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total can...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ERAS
LISTED
NASDAQ
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /CNW/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer dru...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.12.2025
EXOZ
LISTED
NASDAQ
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
News Preview
LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production pro...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
STAA
LISTED
NASDAQ
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC).
Broad...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
HEM
LISTED
TSX
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
News Preview
Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum Mechanics, cosmology, and string theory.Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy com...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
